DNA ligases as therapeutic targets

Translational Cancer Research

Volumn 2, Issue 3, 2013, Pages 203-214

  Tomkinson, Alan E ^a,b,c   Howes, Timothy R L ^d   Wiest, Nathaniel E ^b,d  

^a Gibson LMG   (United States)

^b Molecular Genetics and Microbiology   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; DNA ligase; DNA repair; DNA replication; Genome instability; Mitochondria

Indexed keywords

EID: 84964026613     PISSN: 2218676X     EISSN: 22196803     Source Type: Journal    
DOI: 10.3978/j.issn.2218-676X.2013.04.04     Document Type: Review

References (84)

1. Friedberg EC, Walker GC, Siede W, et al. DNA Repair and Mutagenesis. 2nd ed. ASM Press, 2006.
2. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008;8:363-9.
3. Ellenberger T, Tomkinson AE. Eukaryotic DNA ligases: structural and functional insights. Annu Rev Biochem 2008;77:313-38.
4. Pascal JM, O'Brien PJ, Tomkinson AE, et al. Human DNA ligase I completely encircles and partially unwinds nicked DNA. Nature 2004;432:473-8.
5. Tomkinson AE, Lasko DD, Daly G, et al. Mammalian DNA ligases. Catalytic domain and size of DNA ligase I. J Biol Chem 1990;265:12611-7.
6. Cotner-Gohara E, Kim IK, Hammel M, et al. Human DNA ligase III recognizes DNA ends by dynamic switching between two DNA-bound states. Biochemistry 2010;49:6165-76.
7. De Ioannes P, Malu S, Cortes P, et al. Structural basis of DNA ligase IV-Artemis interaction in nonhomologous end-joining. Cell Rep 2012;2:1505-12.
8. Lakshmipathy U, Campbell C. The human DNA ligase III gene encodes nuclear and mitochondrial proteins. Mol Cell Biol 1999;19:3869-76.
9. Mackey ZB, Ramos W, Levin DS, et al. An alternative splicing event which occurs in mouse pachytene spermatocytes generates a form of DNA ligase III with distinct biochemical properties that may function in meiotic recombination. Mol Cell Biol 1997;17:989-98.
10. Caldecott KW, McKeown CK, Tucker JD, et al. An interaction between the mammalian DNA repair protein XRCC1 and DNA ligase III. Mol Cell Biol 1994;14:68-76.
11. Dulic A, Bates PA, Zhang X, et al. BRCT domain interactions in the heterodimeric DNA repair protein XRCC1-DNA ligase III. Biochemistry 2001;40:5906-13.
12. Nash RA, Caldecott KW, Barnes DE, et al. XRCC1 protein interacts with one of two distinct forms of DNA ligase III. Biochemistry 1997;36:5207-11.
13. Cuneo MJ, Gabel SA, Krahn JM, et al. The structural basis for partitioning of the XRCC1/DNA ligase III-α BRCT-mediated dimer complexes. Nucleic Acids Res 2011;39:7816-27.
14. Cotner-Gohara E, Kim IK, Tomkinson AE, et al. Two DNA-binding and nick recognition modules in human DNA ligase III. J Biol Chem 2008;283:10764-72.
15. Mackey ZB, Niedergang C, Murcia JM, et al. DNA ligase III is recruited to DNA strand breaks by a zinc finger motif homologous to that of poly(ADP-ribose) polymerase. Identification of two functionally distinct DNA binding regions within DNA ligase III. J Biol Chem 1999;274:21679-87.
16. Taylor RM, Whitehouse J, Cappelli E, et al. Role of the DNA ligase III zinc finger in polynucleotide binding and ligation. Nucleic Acids Res 1998;26:4804-10.
17. Grawunder U, Wilm M, Wu X, et al. Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells. Nature 1997;388:492-5.
18. Grawunder U, Zimmer D, Fugmann S, et al. DNA ligase IV is essential for V(D)J recombination and DNA double-strand break repair in human precursor lymphocytes. Mol Cell 1998;2:477-84.
19. Grawunder U, Zimmer D, Kulesza P, et al. Requirement for an interaction of XRCC4 with DNA ligase IV for wild-type V(D)J recombination and DNA double-strand break repair in vivo. J Biol Chem 1998;273:24708-14.
20. Doré AS, Furnham N, Davies OR, et al. Structure of an Xrcc4-DNA ligase IV yeast ortholog complex reveals a novel BRCT interaction mode. DNA Repair (Amst) 2006;5:362-8.
21. Sibanda BL, Critchlow SE, Begun J, et al. Crystal structure of an Xrcc4-DNA ligase IV complex. Nat Struct Biol 2001;8:1015-9.
22. Wu PY, Frit P, Meesala S, et al. Structural and functional interaction between the human DNA repair proteins DNA ligase IV and XRCC4. Mol Cell Biol 2009;29:3163-72.
23. Levin DS, Bai W, Yao N, et al. An interaction between DNA ligase I and proliferating cell nuclear antigen: implications for Okazaki fragment synthesis and joining. Proc Natl Acad Sci U S A 1997;94:12863-8.
24. Montecucco A, Rossi R, Levin DS, et al. DNA ligase I is recruited to sites of DNA replication by an interaction with proliferating cell nuclear antigen: identification of a common targeting mechanism for the assembly of replication factories. EMBO J 1998;17:3786-95.
25. Montecucco A, Savini E, Weighardt F, et al. The N-terminal domain of human DNA ligase I contains the nuclear localization signal and directs the enzyme to sites of DNA replication. EMBO J 1995;14:5379-86.
26. Howes TR, Tomkinson AE. DNA ligase I, the replicative DNA ligase. Subcell Biochem 2012;62:327-41.
27. Vijayakumar S, Dziegielewska B, Levin DS, et al. Phosphorylation of human DNA ligase I regulates its interaction with replication factor C and its participation in DNA replication and DNA repair. Mol Cell Biol 2009;29:2042-52.
28. Levin DS, McKenna AE, Motycka TA, et al. Interaction between PCNA and DNA ligase I is critical for joining of Okazaki fragments and long-patch base-excision repair. Curr Biol 2000;10:919-22.
29. Barnes DE, Tomkinson AE, Lehmann AR, et al. Mutations in the DNA ligase I gene of an individual with immunodeficiencies and cellular hypersensitivity to DNA-damaging agents. Cell 1992;69:495-503.
30. Henderson LM, Arlett CF, Harcourt SA, et al. Cells from an immunodeficient patient (46BR) with a defect in DNA ligation are hypomutable but hypersensitive to the induction of sister chromatid exchanges. Proc Natl Acad Sci U S A 1985;82:2044-8.
31. Bentley D, Selfridge J, Millar JK, et al. DNA ligase I is required for fetal liver erythropoiesis but is not essential for mammalian cell viability. Nat Genet 1996;13:489-91.
32. Bentley DJ, Harrison C, Ketchen AM, et al. DNA ligase I null mouse cells show normal DNA repair activity but altered DNA replication and reduced genome stability. J Cell Sci 2002;115:1551-61.
33. Le Chalony C, Hoffschir F, Gauthier LR, et al. Partial complementation of a DNA ligase I deficiency by DNA ligase III and its impact on cell survival and telomere stability in mammalian cells. Cell Mol Life Sci 2012;69:2933-49.
34. Arakawa H, Bednar T, Wang M, et al. Functional redundancy between DNA ligases I and III in DNA replication in vertebrate cells. Nucleic Acids Res 2012;40:2599-610.
35. Caldecott KW, Tucker JD, Stanker LH, et al. Characterization of the XRCC1-DNA ligase III complex in vitro and its absence from mutant hamster cells. Nucleic Acids Res 1995;23:4836-43.
36. Okano S, Lan L, Caldecott KW, et al. Spatial and temporal cellular responses to single-strand breaks in human cells. Mol Cell Biol 2003;23:3974-81.
37. Tebbs RS, Flannery ML, Meneses JJ, et al. Requirement for the Xrcc1 DNA base excision repair gene during early mouse development. Dev Biol 1999;208:513-29.
38. Puebla-Osorio N, Lacey DB, Alt FW, et al. Early embryonic lethality due to targeted inactivation of DNA ligase III. Mol Cell Biol 2006;26:3935-41.
39. Gao Y, Katyal S, Lee Y, et al. DNA ligase III is critical for mtDNA integrity but not Xrcc1-mediated nuclear DNA repair. Nature 2011;471:240-4.
40. Simsek D, Furda A, Gao Y, et al. Crucial role for DNA ligase III in mitochondria but not in Xrcc1-dependent repair. Nature 2011;471:245-8.
41. Lakshmipathy U, Campbell C. Mitochondrial DNA ligase III function is independent of Xrcc1. Nucleic Acids Res 2000;28:3880-6.
42. Lakshmipathy U, Campbell C. Antisense-mediated decrease in DNA ligase III expression results in reduced mitochondrial DNA integrity. Nucleic Acids Res 2001;29:668-76.
43. Frosina G, Fortini P, Rossi O, et al. Two pathways for base excision repair in mammalian cells. J Biol Chem 1996;271:9573-8.
44. Kubota Y, Nash RA, Klungland A, et al. Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. EMBO J 1996;15:6662-70.
45. Matsumoto Y, Kim K, Hurwitz J, et al. Reconstitution of proliferating cell nuclear antigen-dependent repair of apurinic/apyrimidinic sites with purified human proteins. J Biol Chem 1999;274:33703-8.
46. Teo IA, Arlett CF, Harcourt SA, et al. Multiple hypersensitivity to mutagens in a cell strain (46BR) derived from a patient with immuno-deficiencies. Mutat Res 1983;107:371-86.
47. Teo IA, Broughton BC, Day RS, et al. A biochemical defect in the repair of alkylated DNA in cells from an immunodeficient patient (46BR). Carcinogenesis 1983;4:559-64.
48. Harrison C, Ketchen AM, Redhead NJ, et al. Replication failure, genome instability, and increased cancer susceptibility in mice with a point mutation in the DNA ligase I gene. Cancer Res 2002;62:4065-74.
49. Aboussekhra A, BiggerstaffM, Shivji MK, et al. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell 1995;80:859-68.
50. Araújo SJ, Tirode F, Coin F, et al. Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK. Genes Dev 2000;14:349-59.
51. Moser J, Kool H, Giakzidis I, et al. Sealing of chromosomal DNA nicks during nucleotide excision repair requires XRCC1 and DNA ligase III alpha in a cell-cycle-specific manner. Mol Cell 2007;27:311-23.
52. Caldecott KW. Single-strand break repair and genetic disease. Nat Rev Genet 2008;9:619-31.
53. Amé JC, Rolli V, Schreiber V, et al. PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem 1999;274:17860-8.
54. Ménissier de Murcia J, Ricoul M, Tartier L, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 2003;22:2255-63.
55. Okano S, Lan L, Tomkinson AE, et al. Translocation of XRCC1 and DNA ligase IIIalpha from centrosomes to chromosomes in response to DNA damage in mitotic human cells. Nucleic Acids Res 2005;33:422-9.
56. Katyal S, McKinnon PJ. Disconnecting XRCC1 and DNA ligase III. Cell Cycle 2011;10:2269-75.
57. Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem 2010;79:181-211.
58. San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 2008;77:229-57.
59. DeFazio LG, Stansel RM, Griffith JD, et al. Synapsis of DNA ends by DNA-dependent protein kinase. EMBO J 2002;21:3192-200.
60. Girard PM, Kysela B, Härer CJ, et al. Analysis of DNA ligase IV mutations found in LIG4 syndrome patients: the impact of two linked polymorphisms. Hum Mol Genet 2004;13:2369-76.
61. O'Driscoll M, Cerosaletti KM, Girard PM, et al. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell 2001;8:1175-85.
62. Riballo E, Critchlow SE, Teo SH, et al. Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curr Biol 1999;9:699-702.
63. Barnes DE, Stamp G, Rosewell I, et al. Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryonic mice. Curr Biol 1998;8:1395-8.
64. Frank KM, Sekiguchi JM, Seidl KJ, et al. Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV. Nature 1998;396:173-7.
65. Corneo B, Wendland RL, Deriano L, et al. Rag mutations reveal robust alternative end joining. Nature 2007;449:483-6.
66. Yan CT, Boboila C, Souza EK, et al. IgH class switching and translocations use a robust non-classical end-joining pathway. Nature 2007;449:478-82.
67. Simsek D, Jasin M. Alternative end-joining is suppressed by the canonical NHEJ component Xrcc4-ligase IV during chromosomal translocation formation. Nat Struct Mol Biol 2010;17:410-6.
68. Fattah F, Lee EH, Weisensel N, et al. Ku regulates the non-homologous end joining pathway choice of DNA double-strand break repair in human somatic cells. PLoS Genet 2010;6:e1000855.
69. Nussenzweig A, Nussenzweig MC. A backup DNA repair pathway moves to the forefront. Cell 2007;131:223-5.
70. Lieber MR. NHEJ and its backup pathways in chromosomal translocations. Nat Struct Mol Biol 2010;17:393-5.
71. Simsek D, Brunet E, Wong SY, et al. DNA ligase III promotes alternative nonhomologous end-joining during chromosomal translocation formation. PLoS Genet 2011;7:e1002080.
72. Wang H, Rosidi B, Perrault R, et al. DNA ligase III as a candidate component of backup pathways of nonhomologous end joining. Cancer Res 2005;65:4020-30.
73. Boboila C, Oksenych V, Gostissa M, et al. Robust chromosomal DNA repair via alternative end-joining in the absence of X-ray repair cross-complementing protein 1 (XRCC1). Proc Natl Acad Sci U S A 2012;109:2473-8.
74. Sun D, Urrabaz R. Development of non-electrophoretic assay method for DNA ligases and its application to screening of chemical inhibitors of DNA ligase I. J Biochem Biophys Methods 2004;59:49-59.
75. Tan GT, Lee S, Lee IS, et al. Natural-product inhibitors of human DNA ligase I. Biochem J 1996;314:993-1000.
76. Tseng HM, Shum D, Bhinder B, et al. A high-throughput scintillation proximity-based assay for human DNA ligase IV. Assay Drug Dev Technol 2012;10:235-49.
77. Chen X, Zhong S, Zhu X, et al. Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res 2008;68:3169-77.
78. Zhong S, Chen X, Zhu X, et al. Identification and validation of human DNA ligase inhibitors using computer-aided drug design. J Med Chem 2008;51:4553-62.
79. Srivastava M, Nambiar M, Sharma S, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell 2012;151:1474-87.
80. Sun D, Urrabaz R, Nguyen M, et al. Elevated expression of DNA ligase I in human cancers. Clin Cancer Res 2001;7:4143-8.
81. Sallmyr A, Tomkinson AE, Rassool FV. Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks. Blood 2008;112:1413-23.
82. Tobin LA, Robert C, Rapoport AP, et al. Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias. Oncogene 2013;32:1784-93.
83. Fan J, Li L, Small D, et al. Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy. Blood 2010;116:5298-305.
84. Tobin LA, Robert C, Nagaria P, et al. Targeting abnormal DNA repair in therapy-resistant breast cancers. Mol Cancer Res 2012;10:96-107.